Antibiotic use and risk of Clostridioides difficile infection in patients with inflammatory bowel disease
Journal of Gastroenterology and Hepatology · 2024
DOI: 10.1111/jgh.16720 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2024. Verfasst von Alexis Bejcek und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, Baylor Scott & White Medical Center, Temple, Texas, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Clostridium Infections, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Baylor Scott & White Research Institute.
Abstract (Originalsprache)
Background and Aim Patients with inflammatory bowel disease (IBD) have an increased risk of Clostridioides difficile infection (CDI) compared with those without IBD, which is worsened with antibiotic usage. While prior studies have shown a correlation between CDI development and certain classes of antibiotics, the IBD population has not been well represented. This study evaluates the rates of CDI with outpatient antibiotic use in patients with IBD.
Methods
We conducted a retrospective cohort study composed of patients with IBD and compared the incidence of CDI in patients who received an outpatient prescription for antibiotics (6694 patients) against those without prescriptions (6025 patients) from 2014 to 2020 at our institution. We compared CDI rates based on nine antibiotic classes: penicillins, cephalosporins, sulfonamides, tetracyclines, macrolides, quinolones, clindamycin, metronidazole, and nitrofurantoin.
Results
The risk of CDI was low (0.7%) but significantly higher for those with antibiotic exposure (0.9% vs 0.5%, P = 0.005) and had a positive correlation with a smoking history. The increased risk of CDI in the IBD population was attributable to the clindamycin and metronidazole classes (odds ratio = 4.7, 95% confidence interval: 1.9–11.9, P = 0.001; odds ratio = 3.6, 95% confidence interval: 2.1–6.2, P < 0.0001, respectively).
Conclusions
The use of clindamycin or metronidazole prescribed in an outpatient setting was associated with a statistically significant increased risk of CDI in patients with IBD. Although the association between clindamycin and CDI is a well‐established and common finding, the association between metronidazole and CDI is unique in this study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Department of Medicine, Baylor Scott & White Medical Center, Temple, Texas, USA.
- Division of Internal Medicine, Department of Medicine, Baylor Scott & White Medical Center, Temple, Texas, USA.
- Division of Infectious Diseases, Department of Medicine, Baylor Scott & White Medical Center, Temple, Texas, USA.
- Baylor Scott & White Research Institute, Baylor Scott & White Health, Dallas, Texas, USA.
- Department of Medicine, Baylor College of Medicine, Temple, Texas, USA.
ORCID-Profile: Alexis Bejcek
Förderung
- Baylor Scott & White Research Institute
Zitieren
APA
Bejcek, A., Ancha, A., Lewis, M., Beaver, R., Tecson, K., Bomar, J., & Johnson, C. (2024). Antibiotic use and risk of Clostridioides difficile infection in patients with inflammatory bowel disease. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16720
Vancouver
Bejcek A, Ancha A, Lewis M, Beaver R, Tecson K, Bomar J, et al. Antibiotic use and risk of Clostridioides difficile infection in patients with inflammatory bowel disease. Journal of Gastroenterology and Hepatology. 2024. doi:10.1111/jgh.16720
BibTeX
@article{Bejcek2024,
author = {Bejcek, Alexis and Ancha, Anupama and Lewis, Megan and Beaver, Ryan and Tecson, Kristen and Bomar, Jaccallene and Johnson, Christopher},
title = {Antibiotic use and risk of Clostridioides difficile infection in patients with inflammatory bowel disease},
journal = {Journal of Gastroenterology and Hepatology},
year = {2024},
doi = {10.1111/jgh.16720}
}
EUVIMED